医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2014年
11期
76-77
,共2页
亢春生%刘建新%李彪%张菲菲%贾丽彬
亢春生%劉建新%李彪%張菲菲%賈麗彬
항춘생%류건신%리표%장비비%가려빈
门冬氨酸鸟氨酸%减少%肝动脉化疗栓塞术%轻微型肝性脑病
門鼕氨痠鳥氨痠%減少%肝動脈化療栓塞術%輕微型肝性腦病
문동안산조안산%감소%간동맥화료전새술%경미형간성뇌병
L-ornithine-L-aspartate%reduce%TACE%Minimal hepatic encephalopathy
目的:研究门冬氨酸鸟氨酸减少原发性肝癌肝硬化患者行肝动脉化疗栓塞术后轻微型肝性脑病发生的临床作用。方法100例原发性肝癌肝硬化患者随机分为治疗组和对照组,各50例。治疗组患者在基础保肝治疗上加用门冬氨酸鸟氨酸。对照组给予基础保肝治疗。肝动脉化疗栓塞术后7天行心理智能测试检测。术前1天及术后7天查血氨及相关生化指标。结果治疗组肝动脉化疗栓塞术后轻微型肝性脑病检出6例(12%),对照组28例(56%),χ2=21.57,P<0.001,差异有统计学意义。结论门冬氨酸鸟氨酸能有效降低肝动脉化疗栓塞术后患者的血氨水平,保护肝功能,降低轻微型肝性脑病发病率。
目的:研究門鼕氨痠鳥氨痠減少原髮性肝癌肝硬化患者行肝動脈化療栓塞術後輕微型肝性腦病髮生的臨床作用。方法100例原髮性肝癌肝硬化患者隨機分為治療組和對照組,各50例。治療組患者在基礎保肝治療上加用門鼕氨痠鳥氨痠。對照組給予基礎保肝治療。肝動脈化療栓塞術後7天行心理智能測試檢測。術前1天及術後7天查血氨及相關生化指標。結果治療組肝動脈化療栓塞術後輕微型肝性腦病檢齣6例(12%),對照組28例(56%),χ2=21.57,P<0.001,差異有統計學意義。結論門鼕氨痠鳥氨痠能有效降低肝動脈化療栓塞術後患者的血氨水平,保護肝功能,降低輕微型肝性腦病髮病率。
목적:연구문동안산조안산감소원발성간암간경화환자행간동맥화료전새술후경미형간성뇌병발생적림상작용。방법100례원발성간암간경화환자수궤분위치료조화대조조,각50례。치료조환자재기출보간치료상가용문동안산조안산。대조조급여기출보간치료。간동맥화료전새술후7천행심리지능측시검측。술전1천급술후7천사혈안급상관생화지표。결과치료조간동맥화료전새술후경미형간성뇌병검출6례(12%),대조조28례(56%),χ2=21.57,P<0.001,차이유통계학의의。결론문동안산조안산능유효강저간동맥화료전새술후환자적혈안수평,보호간공능,강저경미형간성뇌병발병솔。
Objective To study the clinical effect of L-ornithine-L-aspartate reducing the incidence rate of Minimal hepatic encephalopathy (MHE) after Transcatheter arterial chemoe-mblization(TACE)operated hepatocel ular carcinoma with cirrhosis patients. Methods 100 cases of patients with hepatocel ular carcinoma accompanying cirrhosis were randomly divided into treatment group and control group, 50 cases in each. Patients in the treatment group were added with ornithine aspartate in foundation treatment. The control group was given basic treatment of liver. 7 days after TACE,intel igent mental test. 1 days before operation and 7 days after operation, blood ammonia and biochemical parameters. Results 6 cases of Minimal hepatic encephalopathy were detected in treatment group TACE after operation (12%), 28 cases in the control group (56%),χ2=21.57 , P <0.001,the difference was statistical y significant. Conclusion L-ornithine-L-aspartate can effectively reduce the level of blood ammonia in patients after TACE, protect the liver function, reduce the incidence rate of Minimal hepatic encephalopathy .